Christian Manegold Roy Herbst More Support for Bevacizumab in Advanced Lung Cancer REFERENCE: Abstract LBA7514, ASCO Annual Meeting Chicago June 1-5, 2007 CHRISTIAN MANEGOLD, Heidelberg University, Ma
Christian Manegold
Roy Herbst
More Support for Bevacizumab in Advanced Lung Cancer
REFERENCE: Abstract LBA7514, ASCO Annual Meeting Chicago June 1-5, 2007
CHRISTIAN MANEGOLD, Heidelberg University, Mannheim
COMMENT: ROY HERBST, MD Anderson Cancer Center, Houston
The benefit of adding bevacizumab to chemotherapy for patients with advanced non-small cell lung cancer was further underlined by a phase III trial presented at ASCO. A European study tested two doses of the targeted agent with or without cisplatin plus gemcitabine chemotherapy. Derek Thorne heard the results from Christian Manegold of the University of Heidelberg.
David Baker
Reduced Chemotherapy: Same Benefit in Pediatric Intermediate Risk Neuroblastoma
REFERENCE: Abstract 9504, ASCO Annual Meeting Chicago June 1-5, 2007
DAVID BAKER, Princess Margaret Hospital, Perth
A phase III study of pediatric patients with neuroblastoma has shown that chemotherapy doses can be reduced whilst maintaining the typical high survival rates of standard dose radiotherapy. Sarah Maxwell talked with investigator David Baker during the ASCO conference.
Robert Mayer
Oral Agent Benefits Patients with Advanced Gastric Cancer
REFERENCE: Abstracts 4513 and 4514, ASCO Annual Meeting Chicago June 1-5, 2007
ROBERT MAYER, Dana-Farber Cancer Institute, Boston
The oral pro-drug known as S-1 has been shown in two Japanese studies to bring survival benefit to patients with advanced gastric cancer. During the ASCO meeting Peter Goodwin asked Robert Mayer for the details and for his assessment of the importance of these new data.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
Related Episodes
Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls
The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies. I’m Peter Goodwin wi
Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025
Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)
Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy
An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon